Equity Overview
Price & Market Data
Price: $55.85
Daily Change: +$2.24 / 4.01%
Daily Range: $54.79 - $56.84
Market Cap: $376,432,864
Daily Volume: 23,070
Performance Metrics
1 Week: 1.53%
1 Month: -4.20%
3 Months: -8.90%
6 Months: -44.09%
1 Year: 92.36%
YTD: -14.81%
Company Details
Employees: 22
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.